Loading clinical trials...
Loading clinical trials...
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Conditions
Interventions
Mirvetuximab Soravtansine
Paclitaxel
+2 more
Locations
214
United States
University of Alabama at Birmingham (UAB) GYN Oncology
Birmingham, Alabama, United States
Alaska Women's Cancer Care
Anchorage, Alaska, United States
Arizona Oncology Associates, PC - HAL - USOR
Phoenix, Arizona, United States
Mayo Clinic
Phoenix, Arizona, United States
USOR: Arizona Oncology Associates, PC - HOPE
Tucson, Arizona, United States
University of Arizona Cancer Center
Tucson, Arizona, United States
Start Date
December 31, 2019
Primary Completion Date
March 6, 2023
Completion Date
October 29, 2024
Last Updated
August 27, 2025
NCT06915025
NCT06710548
NCT02637934
NCT05080946
NCT04657068
NCT05281471
Lead Sponsor
AbbVie
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions